Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

• Váldodahkkit: Katharina Schütz (Dahkki), Sophia Theres Pallenberg (Dahkki), Julia Kontsendorn (Dahkki), David DeLuca (Dahkki), Cinja Sukdolak (Dahkki), Rebecca Minso (Dahkki), Tina Büttner (Dahkki), Martin Wetzke (Dahkki), Christian Dopfer (Dahkki), Annette Sauer-Heilborn (Dahkki), Felix C. Ringshausen (Dahkki), Sibylle Junge (Dahkki), Burkhard Tümmler (Dahkki), Gesine Hansen (Dahkki), Anna-Maria Dittrich (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in June 2021 for pwCF ≥6 yrs of age. In this single...